Stock BIOBV BIOHIT OYJ
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Biohit Oyj

Equities

BIOBV

FI0009005482

Market Closed - Nasdaq Helsinki
Other stock markets
 12:00:00 2024-07-12 pm EDT 		5-day change 1st Jan Change
2.08 EUR +0.48% Intraday chart for Biohit Oyj +0.97% +10.34%
Jun. 14 Finland's Biohit Names Chief Technology Officer MT
Jun. 14 Biohit Oyj Announces Management Appointments, Effective August 12, 2024 CI

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

  • Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 47% by 2026.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

  • The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.

Ratings chart - Surperformance

Sector: Office Equipment

1st Jan change Capi. Investor Rating ESG Refinitiv
BIOHIT OYJ Stock Biohit Oyj
+10.34% 34.42M -
SHIMADZU CORPORATION Stock Shimadzu Corporation
+8.63% 7.99B
B-
TECAN GROUP AG Stock Tecan Group AG
-5.94% 4.63B
B
OLINK HOLDING AB Stock Olink Holding AB
+3.70% 3.25B -
JEOL LTD. Stock JEOL Ltd.
+12.70% 2.26B -
ECKERT & ZIEGLER SE Stock Eckert & Ziegler SE
+10.07% 1.03B
C+
NINGBO YONGXIN OPTICS CO.,LTD Stock Ningbo Yongxin Optics Co.,Ltd
-37.02% 959M -
PARK SYSTEMS CORP. Stock Park Systems Corp.
+1.44% 888M -
FOCUSED PHOTONICS (HANGZHOU), INC. Stock Focused Photonics (Hangzhou), Inc.
-29.34% 693M -
MLOPTIC CORP. Stock MLOptic Corp.
-58.26% 660M -
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. BIOBV Stock
  4. Ratings Biohit Oyj